FOLH1 and neoplasm: Circulating tumor cell (CTC) counts (>5 cells/7.5 mL) and ctDNA (such as AR-V7) predict ARPI resistance, favoring PSMA-targeted therapies for rib lesions, yet require standardized assays [36,37].